A Phase 1/2, Open-Label, Multicenter, Single-Arm Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease

About the study

This is an open label, multicenter, Phase 1/2 study in approximately eight adults with severe
Sickle Cell Disease (SCD). The study will evaluate the safety, tolerability, and efficacy of
autologous hematopoietic stem cell transplantation using BIVV003.

Study point of contact

Trial Transparency email recommended (Toll free number for US & Canada)
800-633-1610 ext 6
[email protected]


5 United States sites


18 to 40 Years




Phase 1/Phase 2

Study type










participation requirements

– Ages 18 to 40

– Confirmation of sickle cell disease (SCD) diagnosis (HbSS or HbS[beta]0 genotype)

– Severe SCD, defined as having 1 or more of the following manifestations: Clinically
significant neurologic event (example [e.g.], stroke) or any neurological deficit
lasting more than 24 hours; History of 2 or more episodes or Acute Chest Syndrome
(ACS) in 2 years prior to informed consent (despite adequate supportive therapies such
as asthma therapy); Six or more pain crises per year in 2 years prior to informed
consent (requiring intravenous [IV] pain management in the outpatient or inpatient
hospital setting); History of 2 or more cases or priapism with participant seeking
medical care in the 2-years prior to informed consent; Regular RBC transfusion therapy
in the year prior to informed consent (having received 8 or more transfusions to
prevent vaso-occlusive clinical complications); and Echocardiographic finding of
tricuspid valve regurgitant jet (TRJ) velocity of greater than or equal to 2.5 meter
per second (m/s)

– Clinically stable to undergo stem cell mobilization and myeloablative hematopoietic
stem cell transplantation (HSCT)

– Adequate physiological function, defined as the following: Karnofsky/Lansky
Performance of greater than or equal to 60; Acceptable cardiac function as defined in
protocol; Acceptable pulmonary function as defined in protocol; Acceptable renal
function as defined in protocol; and Acceptable hepatic function as defined in

– Ability to understand purpose and risks of study, provide Informed Consent Form (ICF)
and authorization to use protected health information

– Completion of age-appropriate cancer screening

– Willingness to use double-barrier method of contraception through entire study period
(for participants of childbearing potential)

– Willingness to receive blood transfusions

– Willingness to discontinue hydroxyurea (HU) at least 30 days prior to stem cell
mobilization through Day 100 post-transplantation

participation restrictions

– Previous receipt of an autologous or allogeneic HSCT or solid organ transplantation

– Previous treatment with gene therapy

– Current enrollment in an interventional study or having received an investigational
drug within 30 days of study enrollment

– Pregnant or breastfeeding female

– Female or male who plans to become pregnant or impregnate a partner, respectively,
during the anticipated study period

– Contraindication to plerixafor, apheresis, or busulfan

– Treatment with prohibited medication in previous 30 days

– Known allergy or hypersensitivity to plerixafor, busulfan, or investigational product

– History of active malignancy within past 5 years, any history of hematologic
malignancy, or a family history of a cancer predisposition syndrome (without negative
result of candidate)

– Current diagnosis of uncontrolled seizures

– History of significant bleeding disorder

– Clinically significant infection

– Any major organ dysfunction involving brain, kidney, liver, lung, or heart (e.g.,
congestive heart failure, pulmonary hypertension)

– Corrected QT interval of more than 500 millisecond (ms) based on screening
electrocardiogram (ECG)

– Positive for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis
C virus (HCV)

– Known to have a gamma-globin variant associated with altered oxygen affinity

– Hereditary persistence of fetal hemoglobin (HPFH) or HbF concentration of more than or
equal to 20 percent (%) at screening

– Absolute Neutrophil Count (ANC) of less than or equal to 1,000 per microliter

– Platelet count of less than 100,000 per microliter

– History of platelet alloimmunization (precluding ability to provide transfusion

– Extensive Red Blood Cell (RBC) alloimmunization (precluding ability to provide
transfusion support)

– Judged unsuitable for participation by investigator and/or sponsor


  • Oakland, California, United States, UCSF Benioff Children's Hospital, 94609 [Recruiting]
  • Sacramento, California, United States, University of California Davis Comprehensive Cancer Center, 95817 [Recruiting]
  • Atlanta, Georgia, United States, Children's Healthcare of Atlanta, 30322 [Recruiting]
  • Bethesda, Maryland, United States, Investigational Site Number 101, 20892 [Recruiting]
  • Detroit, Michigan, United States, Karmanos Cancer Institute, 48201 [Recruiting]
Last updated 2021-02-17